Trelagliptin

DB15323InvestigationalSmall molecule

Trelagliptin is a dipeptidyl peptidase-4 inhibitor indicated in the control of diabetes mellitus. Trelagliptin is under investigation in clinical trial NCT03555591 (Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus").

Chemical structure of Trelagliptin
Formula / weight
C18H20FN5O2 · 357.389 g/mol (avg)

Resolves to

Compound
UNIIQ836OWG55HCAS865759-25-7ChEMBLCHEMBL1650443ChEBI134715
Structure
InChIKeyIWYJYHUNXVAVAA-OAHLLOKOSA-NSMILESCN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=CC(F)=CC=C2C#N)C1=O
Targets
P27487DPP4

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Trelagliptin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In